MiRNA therapeutics based on logic circuits of biological pathways

In silico experiments, with the aid of computer simulation, speed up the process of in vitro or in vivo experiments. Cancer therapy design is often based on signalling pathway. MicroRNAs (miRNA) are small non-coding RNA molecules. In several kinds of diseases, including cancer, hepatitis and cardiovascular diseases, they are often deregulated, acting as oncogenes or tumor suppressors. miRNA therapeutics is based on two main kinds of molecules injection: miRNA mimics, which consists of injection of molecules that mimic the targeted miRNA, and antagomiR, which consists of injection of molecules inhibiting the targeted miRNA. Nowadays, the research is focused on miRNA therapeutics. This paper addresses cancer related signalling pathways to investigate miRNA therapeutics. In order to prove our approach, we present two different case studies: non-small cell lung cancer and melanoma. KEGG signalling pathways are modelled by a digital circuit. A logic value of 1 is linked to the expression of the corresponding gene. A logic value of 0 is linked to the absence (not expressed) gene. All possible relationships provided by a signalling pathway are modelled by logic gates. Mutations, derived according to the literature, are introduced and modelled as well. The modelling approach and analysis are widely discussed within the paper. MiRNA therapeutics is investigated by the digital circuit analysis. The most effective miRNA and combination of miRNAs, in terms of reduction of pathogenic conditions, are obtained. A discussion of obtained results in comparison with literature data is provided. Results are confirmed by existing data. The proposed study is based on drug discovery and miRNA therapeutics and uses a digital circuit simulation of a cancer pathway. Using this simulation, the most effective combination of drugs and miRNAs for mutated cancer therapy design are obtained and these results were validated by the literature. The proposed modelling and analysis approach can be applied to each human disease, starting from the corresponding signalling pathway.

[1]  A. Tolcher,et al.  A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Rossi,et al.  The potential role of mTOR inhibitors in non-small cell lung cancer. , 2008, The oncologist.

[3]  A. Datta,et al.  From biological pathways to regulatory networks , 2010, 49th IEEE Conference on Decision and Control (CDC).

[4]  P. Starostik,et al.  Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. , 2015, Archives of pathology & laboratory medicine.

[5]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[6]  Gaetano Rocco,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.

[7]  C. Gridelli,et al.  Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  L. J. Veer,et al.  N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.

[9]  Wei Zhong,et al.  Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer , 2018, Thoracic cancer.

[10]  Li Ding,et al.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.

[11]  Hsien-Da Huang,et al.  miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions , 2017, Nucleic Acids Res..

[12]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Francesca D. Ciccarelli,et al.  NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings , 2015, Nucleic Acids Res..

[14]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[15]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[16]  George A. Calin,et al.  microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.

[17]  R. Sahu,et al.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[18]  Dong Sun Kim,et al.  PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.

[19]  Judy Lieberman,et al.  Micromanaging hepatitis C virus. , 2013, The New England journal of medicine.

[20]  K. Rauen,et al.  Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome , 2011, Clinical genetics.

[21]  S. Khatri,et al.  Application of Max-SAT-based ATPG to optimal cancer therapy design , 2012, BMC Genomics.

[22]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[23]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[24]  J. E. Kim,et al.  microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer , 2016, Biological reviews of the Cambridge Philosophical Society.

[25]  Jacqueline L Olin,et al.  Alectinib for advanced ALK-positive non-small-cell lung cancer. , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[26]  Zhongming Zhao,et al.  TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes , 2015, Nucleic Acids Res..

[27]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[28]  C. Croce,et al.  Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. , 2009, Blood.

[29]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[30]  Matthias Rothmund,et al.  CDKN2A Germline Mutations in Familial Pancreatic Cancer , 2002, Annals of surgery.

[31]  Chao Huang,et al.  Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. , 2018, Lung cancer.

[32]  Seyed Javad Mowla,et al.  Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. , 2016, The international journal of biochemistry & cell biology.

[33]  Antonio Marchetti,et al.  Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features , 2006, International journal of cancer.

[34]  S. Popat,et al.  Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2018, The New England journal of medicine.

[35]  Silvia Catuogno,et al.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[37]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[38]  Yang Zhao,et al.  The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials , 2018, Journal of Cancer.

[39]  Ning Liu,et al.  Regulation of let-7 and its target oncogenes (Review). , 2012, Oncology letters.

[40]  Antonino Fiannaca,et al.  miRTissue: a web application for the analysis of miRNA-target interactions in human tissues , 2018, BMC Bioinformatics.

[41]  P. Khavari,et al.  Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.

[42]  Ji Luo,et al.  Development of siRNA payloads to target KRAS-mutant cancer. , 2014, Cancer discovery.

[43]  Stefano Volinia,et al.  Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. , 2009, International journal of oncology.

[44]  Massimo Libra,et al.  Melanoma: molecular pathogenesis and emerging target therapies (Review). , 2009, International journal of oncology.

[45]  A. Bosserhoff,et al.  Role of miRNAs in the progression of malignant melanoma , 2009, British Journal of Cancer.

[46]  Jun Li,et al.  miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways , 2016, Oncotarget.

[47]  Alessandro Beghini,et al.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. , 2010, Neoplasia.

[48]  Roy Parker,et al.  The Two Faces of miRNA , 2007, Science.

[49]  Michael F. Olson,et al.  RAS and RHO GTPases in G1-phase cell-cycle regulation , 2004, Nature Reviews Molecular Cell Biology.

[50]  Carl Burch,et al.  Logisim: a graphical system for logic circuit design and simulation , 2002, JERC.

[51]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[52]  Aniruddha Datta,et al.  Hypoxia Stress Response Pathways: Modeling and Targeted Therapy , 2017, IEEE Journal of Biomedical and Health Informatics.

[53]  Aniruddha Datta,et al.  Systems biology Advance Access publication December 30, 2010 Cancer therapy design based on pathway logic , 2022 .

[54]  Ghayda M. Mirzaa,et al.  PIK3CA-Related Segmental Overgrowth , 2013 .

[55]  Thomas D. Schmittgen,et al.  microRNA Replacement Therapy for Cancer , 2011, Pharmaceutical Research.

[56]  Aniruddha Datta,et al.  Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer , 2017, BMC Bioinformatics.

[57]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[58]  Edwin Cuppen,et al.  A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability , 2012, PloS one.

[59]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[60]  Tae Min Kim,et al.  An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer , 2016 .

[61]  Aniruddha Datta,et al.  A Model for Cancer Tissue Heterogeneity , 2014, IEEE Transactions on Biomedical Engineering.

[62]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[63]  Ken R. Bracke,et al.  miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD , 2020, Frontiers in Medicine.

[64]  Mitsuo Sato,et al.  Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells , 2015, Cancer medicine.

[65]  Aniruddha Datta,et al.  Using the message passing algorithm on discrete data to detect faults in boolean regulatory networks , 2014, Algorithms for Molecular Biology.

[66]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[67]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[68]  Manfred Kunz,et al.  MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.

[69]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[70]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[71]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[72]  T. Catela Ivković,et al.  microRNAs as cancer therapeutics: A step closer to clinical application. , 2017, Cancer letters.

[73]  Franck Morin,et al.  Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study , 2018, European Respiratory Journal.

[74]  Ping Yang,et al.  miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican , 2017, Experimental and therapeutic medicine.

[75]  F. Slack,et al.  Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.

[76]  J. Chorostowska-Wynimko,et al.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives , 2017, Targeted Oncology.

[77]  Edward B. Garon,et al.  Targeting MEK for the treatment of non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[79]  Matteo Bottai,et al.  Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma , 2018, PloS one.

[80]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[81]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[82]  Dara L. Aisner,et al.  Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung , 2018, Cold Spring Harbor molecular case studies.